Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population

Cancer

Volumn 116, Issue 13, 2010, Pages 3112-3118

  Toi, Masakazu ^a   Iwata, Hiroji ^b   Yamanaka, Takeharu ^c   Masuda, Norikazu ^d   Ohno, Shinji ^c   Nakamura, Seigo ^e   Nakayama, Takahiro ^f   Kashiwaba, Masahiro ^g   Kamigaki, Shunji ^h   Kuroi, Katsumasa ⁱ   Ueno, Takayuki ^a   Aogi, Kenjiro ^j  

^a KYOTO UNIVERSITY   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^f OSAKA UNIVERSITY   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

^h SAKAI MUNICIPAL HOSPITAL   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

more..

Author keywords

Breast cancer; Gene signature; Proliferation; Recurrence

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY CANCER; GENE EXPRESSION; HUMAN; JAPANESE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURGICAL APPROACH; SURGICAL TECHNIQUE;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE; RISK;

EID: 77954290417     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25206     Document Type: Article

References (12)

1. Kono A, Misumi J. The time trend of breast cancer mortality in Japan. Arch Gynecol Obstet. 2005;272:187-190. (Pubitemid 41413985)
2. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptasepolymerase chain reaction assay. Am J Pathol. 2004;164:35-42. (Pubitemid 38364587)
3. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53:1084-1091. (Pubitemid 46867525)
4. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
5. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.
6. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
7. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
8. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v. 2.2008. Available at: http://www.nccn.org. Accessed on August 1, 2009.
9. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer [abstract]. Presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 10.
10. Dowsett M, Cuzick J, Wales C, et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study [abstract]. Presented at: the 31st Annual San Antonio Breast Cancer Symposium, December 2008; San Antonio, TX. Abstract 53.
11. The general rules for clinical and pathological recording of breast cancer. Jpn J Surg. 1989;19:612-632. (Pubitemid 20044125)
12. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy endpoints in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127-2132.